CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers

Tejinder Kataria¹ Pushpa Nagá¹ Susovan Banerjee¹ Deepak Gupta¹ Kushal Narang¹ Manoj Tayal¹ Shyam Singh Bisht¹

¹Division of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India

Address for correspondence Susovan Banerjee, MD, Division of Radiation Oncology, Medanta - The Medicity, Sector 38, Gurgaon 122001, Haryana, India (e-mail: drsusovan@gmail.com).

South Asian J Cancer

Abstract

Purpose Use of stereotactic ablative radiotherapy (SABR) in the treatment of recurrent or metastatic lesions from a primary gynecologic cancer is a relatively new concept. The present study aims to assess the safety, efficacy, and possible toxicity profile of CyberKnife SABR, recurrent or metastatic disease.

Materials/Methods CyberKnife VSI-based SABR was offered to 20 oligometastatic/recurrent gynecological cancer patients between 2013 and 2019. Patient, tumor, and treatment characteristics including radiotherapy details, clinical outcome in terms of local control rates, and toxicities are reported in this study.

Results Twenty-five recurrent or oligometastatic lesions for 20 primary gynecologic cancer patients including cervical (n = 8), ovarian (n = 6), endometrial (n = 5), and vulvar (n = 1) cancers were analyzed. Of these, 4 (16%) were intracranial lesions and remaining 21 (84%) were extracranial, consisting of 14 (67%) extrapelvic and 7 (33%) pelvic lesions. The median SABR dose delivered was 60 Gy biologically effective dose (range 42–133 Gy) in an average of four fractions (range 1–6). The mean follow-up was 18 (range 2–70) months. Local tumor control was achieved in 82% of patients. There was no grade ≥ 3 toxicity recorded.

Conclusion Our study results suggest that CyberKnife SABR is an effective treatment modality with no major morbidity in patients with recurrent or oligometastatic gynecological cancers.

Introduction

Gynecological cancers are among the most common cancers affecting women in India. Despite the available treatment for primary gynecologic cancers, recurrence rates range from 10 to 60%¹ within first 2 to 3 years of treatment and 15 to 20% experience metastasis, often with a dismal prognosis.²

There is no standard of care defined for patients with recurrent/metastatic disease because of heterogeneous manifestations and the outcome has not been adequately addressed in the literature. Few anecdotal report suggests, 5-year postrelapse survival rates of 5 to 16% and a selective subgroup of patients with limited disease, may benefit from salvage therapy providing durable disease control.³

Stereotactic ablative radiation therapy (SABR) involves an accurate delivery of a high dose of radiation in few fractions to a target with narrow or no margins. It has been proven to be a valuable tool in the treatment of a variety of recurrent cancers.
or metastatic tumors in the recent years. Use of CyberKnife SABR as a salvage treatment option in unresectable, limited recurrent/metastatic gynecologic malignancies, such as cervical, vaginal, vulvar, and uterine cancer, is a relatively new concept. Its safety and efficacy in this setting is not been reported.

With an aim to evaluate and report our clinical experience of CyberKnife SABR in recurrent or oligometastatic gynecologic cancers, the electronic health information center records of 20 cases treated consecutively from January 2013 to December 2019 were analyzed.

Materials and Methods

Between January 2013 and October 2019, patients with histologically proven recurrent or metastatic gynecological cancers who were treated with stereotactic radiotherapy using the CyberKnife VSI system (Accuray Inc., Sunnyvale, California, United States) were enrolled for the study. The electronic medical records of all patients were reviewed. Patient demographics including age, stage, tumor characteristics, treatment details, toxicity, and clinical outcome parameters were recorded, compiled, and analyzed.

CyberKnife Stereotactic Ablative Radiotherapy
CyberKnife irradiation was considered in case of unresectable, limited recurrent, ≤ 5 metastatic lesions with controlled primary gynecologic disease and for residual disease in case of recurrent/metastatic lesions after surgery or systemic chemotherapy.

All the patients were evaluated with whole body positron emission tomography and computed tomography (PET/CT) scans prior to treatment. Written informed consent was obtained from each patient. Patients were immobilized in the required treatment positions with appropriate immobilization devices, either using thermoplastic masks or Vac-Lok Cushion (CIVCO Medical Solutions, Orange City, Iowa, United States).

CyberKnife planning CT simulation (Siemens Medical Systems, USA, Inc) was performed by acquisition of both noncontrast and contrast (intravenous, Iobitridol [Xenetix]) CT images with 1 mm slice thickness. Following acquisition, all image sets were transferred to Multiplan v4.6.0 (Accuray Inc.) treatment planning system. Tumor volumes and organ-at-risks (OARs) were contoured on noncontrast CT images according to the institutional protocol. The gross tumor volume (GTV) was defined as visible tumor on contrast planning enhanced CT, PET/CT, and/or magnetic resonance imaging (MRI) images fused for better target delineation. The GTV was considered to be identical as clinical target volume (CTV). The planning target volume (PTV) included a margin expansion of 2 to 5 mm to CTV.

Treatment planning was performed on noncontrast CT image data sets. The prescription doses were determined considering multiple factors, such as tumor volume, previous radiation doses, critical consideration of adjacent organs, and number of fractions. Dose was typically prescribed to the 70 to 85% isodose line of the maximum dose to cover 98 to 99% of PTV (Fig. 1). Plans were evaluated qualitatively by examining prescribed reference isodose to adequately cover the target volume in all dimensions and quantitatively by recording Dmean, D2%, D95%, and D98% (the dose received by mean, 2%, 95%, and 98%, respectively) of the target volume, homogeneity indices (HIs), conformity indices (CI), and dose to corresponding adjacent OAR. Dose fractionations were normalized to 2-Gy equivalent doses (Eq. D2) and biologically effective dose (BED) with α/β ratio of 10 Gy for tumor and 3 Gy for normal tissues. Treatment was delivered on CyberKnife VSI system. Tumors tracking systems were used as indicated. Adequate bowel preparation instructions were given at simulation and treatment. All patients were advised low fiber diet, laxatives as required, and activated charcoal tablets to minimize the uncertainties related to bowel movement and bowel gas. Additional adjuvant treatments including systemic chemotherapy, hormone therapy, and targeted therapy were considered whenever indicated.

PET-based radiological imaging and clinical follow-up were performed at 10 to 12 weeks posttreatment for treatment response evaluation. Thereafter, all patients were followed-up with clinical examination every 3 months in first 2 years and PET/CT every year. Subsequent clinical examination was scheduled at 6 months for 3 more years.

Tumor response was assessed using Response Evaluation and Criteria in Solid Tumors. Local failure was defined as an increase in the targeted tumor size or the presence of a new lesion in the radiation field. However, if a new lesion developed outside the radiation field, it was interpreted as distant metastasis.

Acute and late toxicities were defined as symptoms that developed within 3 months posttreatment or later, respectively, and graded according to the Radiation Therapy Oncology Group/European Organization for Research and the Treatment of Cancer (RTOG/EORTC) radiation toxicity scoring system.

Statistical Analyses
Statistical analysis was performed using Statistical Program for Social Sciences software for Windows (SPSS Inc., Version 26, Chicago, Illinois, United States). Kaplan–Meier’s method was used to calculate local control (LC) rates.
Results

Patient and Tumor Characteristics

Table 1 shows patient and tumor characteristics in detail. Twenty primary gynecological cancer patients with 25 biopsy-proven recurrent or oligometastatic lesions underwent CyberKnife SABR. With a median age of 60 years (range, 40–82; mean, 59 years), 8 patients (40%) were primary cervical, 6 (30%) were ovarian, 5 (25%) were endometrial, and 1 patient (5%) had vulvar cancer. Of these, 17 patients were proven to have isolated recurrent/metastatic disease and 3 had more than one recurrent/metastatic disease (2 patients had two lesions and 1 patient had four lesions) seen on PET/CT. Four (16%) intracranial and 21 (84%) extracranial lesions including 14 (67%) extrapelvic and 7 (33%) pelvic lesions were treated. Fourteen (70%) patients had prior pelvic radiation therapy (RT) as part of the initial primary treatment (7 had lesions outside RT field and the remaining 7 had lesions within RT field). Two (10%) lesions were partially overlapped with previous RT field and the remaining 7 had lesions outside RT field. Median time to recurrence among patients with prior RT was 32 months (range, 5–120 months).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Classification</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y (n = 20)</td>
<td>Median (range)</td>
<td>60 (40–82)</td>
</tr>
<tr>
<td>Primary tumor (n = 20)</td>
<td>Cervix</td>
<td>8 (40)</td>
</tr>
<tr>
<td></td>
<td>Endometrium</td>
<td>5 (25)</td>
</tr>
<tr>
<td></td>
<td>Ovary</td>
<td>6 (30)</td>
</tr>
<tr>
<td></td>
<td>Vulva</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Histology (n = 20)</td>
<td>Squamous cell carcinoma</td>
<td>7 (35)</td>
</tr>
<tr>
<td></td>
<td>Adenocarcinoma</td>
<td>12 (60)</td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Previous history of pelvic radiation (n = 20)</td>
<td>Yes</td>
<td>14 (70)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>6 (30)</td>
</tr>
<tr>
<td>CK-SABR treatment setting (n = 25)</td>
<td>1st time recurrent/metastatic</td>
<td>13 (52)</td>
</tr>
<tr>
<td></td>
<td>Re-recurrent/metastatic</td>
<td>12 (48)</td>
</tr>
<tr>
<td>CK-SABR site (n = 25)</td>
<td>Lymph nodes - Paraaortic</td>
<td>9 (36)</td>
</tr>
<tr>
<td></td>
<td>Lymph nodes - Others</td>
<td>3 (12)</td>
</tr>
<tr>
<td></td>
<td>Lung</td>
<td>5 (20)</td>
</tr>
<tr>
<td></td>
<td>Brain</td>
<td>4 (16)</td>
</tr>
<tr>
<td></td>
<td>Bone</td>
<td>2 (8)</td>
</tr>
<tr>
<td></td>
<td>Soft tissue deposit</td>
<td>1 (4)</td>
</tr>
<tr>
<td></td>
<td>Vaginal vault deposit</td>
<td>1 (4)</td>
</tr>
</tbody>
</table>

Abbreviations: CK, CyberKnife; SABR, stereotactic ablative radiotherapy.

Treatment Characteristics

CyberKnife SABR was performed as a first-line therapy in 11 (55%) patients and for recurrent/metastatic disease in 9 (45%) patients. A total of 25 treated lesions included 13 (52%) post-chemotherapy residual recurrent/metastatic disease, 5 (20%) new metastatic lesions, 3 (15%) post-RT recurrent lesions, 2 (8%) postop post-RT post-chemo residual, 1 (4%) post-chemo post-RT residual, and 1 (4%) postop recurrent/metastatic disease.

The target volumes, GTV ranged from 0.7 to 30 cm³ (mean 9 cm³, median 8 cm³) and the PTV ranged from 3 to 280 cm³ (mean 40 cm³, median 17 cm³). Dose was prescribed to the 60 to 86% (median 80%) isodose line. The prescription dose ranged from 15 to 35 Gy (median 30 Gy) and the median SABR dose delivered was 60 Gy BED (range, 42–133) in an average of four fractions (range, 1–6). In two patients with solitary brain metastasis, single-fraction stereotactic radio surgery was done delivering 20 Gy to PTV. Overall, mean (± standard deviation [SD]) CyberKnife SABR duration was 6 days (±3 days). Mean (±SD) percentage dose received by Dmean, D2%, D95%, and D98% was 110% (±6.1), 123% (±6.1), 99.5% (±8.5), and 96.4% (±9.8), respectively. The mean value of HI was 27 (range, 11–56) and CI was 1.2 (range, 1–2). All targets were tracked during treatment delivery using Xsight Spine (n = 14, 56%), 6D skull (n = 4, 16%), fiducials (n = 4, 16%), and synchrony (n = 3, 12%) tracking systems. After completion of CyberKnife SABR, 9 patients continued to receive additional treatment including systemic chemotherapy in 6 and hormone therapy in 3 patients.

Treatment Response and Follow-Up

Eighteen patients underwent PET/CT and one had MRI scan at approximately 8 to 12 weeks after treatment. One patient was lost to follow-up after completing SABR, and hence response could not be evaluated. On response evaluation imaging by first 3 months, 9 (47.5%), 5 (26%), 4 (21%), and 1 (5.5%) of the 19 patients had complete response (CR), partial response (PR), progressive disease, and stable disease, respectively. During the subsequent follow-up imaging, two patients of PR achieved CR and six more patients (3 of 9 CR patients and 3 of 5 PR) were diagnosed with disease relapse/progression.

Therefore, out of 19 patients, 8 (42%) patients were disease-free and remaining 11 (58%) were detected with disease progression, including local progression and/or distant metastasis. Of these, two patients had local progression, eight had distant visceral/lymph nodal metastasis, and one had both local progression and distant metastasis. Among 11 relapses, a patient with local progression was salvaged with surgery whereas remaining patients received either palliative chemotherapy or radiation or symptomatic treatment only.

With a mean follow-up of 18 (range, 2–70) months, all of the 7 disease-free patients along with one patient with second primary meningioma were alive and healthy with average follow-up period of 25 months. Of the 11 relapses, one of the relapsed patients died due to the disease after 7 months of treatment completion, and 3 patients were lost to follow-up after a minimum follow-up period of 4 months.
Local Control and Toxicity

Local tumor control was achieved in 82% of patients. Overall acute toxicity was observed in 9 (45%) of the 20 patients. The most common grade 1 to 2 adverse events during the treatment were nausea and vomiting (n = 3, 15%), gastrointestinal (GI) toxicity (n = 2, 10%), fatigue (n = 2, 10%), and genitourinary toxicity (n = 1, 5%). In one patient with grade 2 GI toxicity, planned treatment was concluded a fraction earlier in view of poor tolerance and worsening general condition and was lost to response evaluation later. No acute grade 3 to 4 toxicities occurred, and no late toxicities were recorded.

Discussion

The management of patients with recurrent or oligometastatic gynecological cancers is challenging. Achieving an early and optimal LC of recurrent or oligometastatic lesion in cases with controlled primary is the key factor for favorable outcome. Therapeutic efficacies of various local treatment modalities including RT, surgery, radiofrequency ablative therapy, and combination therapy have been explored. Considering its efficacy and minimum invasiveness, RT is a more viable and feasible option in most cases in contrast to surgery. However, conventional radiation technique is limited by the virtue of its potential toxicity to OARs to deliver radical doses. SABR using CyberKnife enables to deliver high radiation dose with submillimeter precision to the target allowing narrow margins and thus relatively sparing nearby OAR structures.10-12

Our series consisted of 4 (16%) intracranial, 14 (56%) extrapelvic, and 7 (28%) intrapelvic lesions. The observed 1-year overall survival (OS) was 94% and local tumor control was achieved in 82% of patients.

An intriguing observation of our study is that more than half of the cases were extrapelvic lesions in contrast to the published series.13 Patients with extrapelvic recurrent/metastatic disease generally have poor clinical outcomes, with a reported 5-year OS of less than 20%.14 It is noteworthy that, in our series 11 of the 14 patients (78%) with extrapelvic lesions had achieved LC by 1 year with median OS of 19 months. Notably, patients with solitary recurrences had a relatively better progression-free survival (PFS) and OS than those with multiple lesions (2-year PFS, 56% vs. 40% and 2-year OS, 96% vs. 88%).

There is no much literature published or any standard recommendations for dose fractionation schedule for the use of SABR for recurrent or oligometastatic gynecological cancers. With the available evidence, the BED doses delivered vary from 60 to 90 Gy. In our series, patients received a median SABR dose of 60 Gy BED (range, 42–133) in an average of four fractions (range, 1–6), which is slightly lower in comparison to another series reported by a Korean group.14 Because of the diverse recurrent/metastatic sites and heterogeneous patient status, it is difficult to determine the optimal dose for tumor control. It might be reasonable to determine the treatment dose individually based on dose constraints of adjacent organs.

Recently, owing to availability of more sensitive methods of detection, recurrent/oligometastatic states are more frequently identified than before. Site of recurrence/metastasis, type of initial primary therapy, and disease-free interval have vital implication on further management of these lesions.14 In general, an early identification and LC of recurrences before progression to disseminated disease may improve patient outcomes.

The limitations of our study include small sample size, retrospective nature of data, and heterogeneous target population. Nevertheless, it is an early experience of a single institution representing data from a low-middle income country in a realistic scenario. Our data indicate that patients with recurrent or oligometastatic gynecological cancers do not invariably have a dismal prognosis. CyberKnife SABR can be an effective local therapy for recurrent/metastatic gynecological cancers with curative potential. It would be interesting to explore outcome of SABR with further addition of systemic therapy intervention strategies like immunotherapy and/or targeted therapy for better salvage rates.

Conclusion

CyberKnife SABR offers an effective and safe approach for selected cases of recurrent or oligometastatic gynecologic cancers. Initial outcomes are encouraging with good LC and acceptable toxicity. The efficacy and toxicity need to be evaluated over the long term. Further, large-scale studies are required to define optimal target doses, dose–response relationship, and OAR limits.

References